Forgetting About The Heart: Low Utilization Of Renin-Angiotensin-Aldosterone System Inhibitors, Echocardiography, And Cardiology Follow-Up In Renal Transplant Recipients With Heart Failure With Reduced Ejection Fraction

Michael Hill,Kaitlyn Legg,Amer Ardati,Vicki Groo

DOI: https://doi.org/10.1016/j.cardfail.2023.10.159

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Heart failure with reduced ejection fraction (HFrEF) confers significant risk of mortality and hospitalization in patients with end-stage renal disease (ESRD). Renal transplant (RT) recipients with HFrEF may experience recovery in left ventricular ejection fraction (LVEF), but RT recipients rarely continue RAAS inhibitors (RAASi) due to concerns for adverse effects including hyperkalemia, anemia, or increases in serum creatinine (SCr). We sought to characterize RAASi use in RT recipients with HFrEF and investigate whether post-RT RAASi introduction was associated with measures of renal function, LVEF, or cardiology follow-up. Methods We retrospectively evaluated adults ≥18 years old at University of Illinois Health (UIH) who underwent RT between 1/1/2015-11/20/2020 with LVEF<40% on transthoracic echocardiogram (TTE) at any point before transplant. The primary outcome was RAASi use within 2 years after RT. Secondary outcomes included SCr (mg/dL), estimated glomerular filtration rate (eGFR; mL/min), potassium (K; mg/dL), mean arterial pressure (MAP, mmHg), cardiology follow-up, and LVEF on TTE ≥90d after transplant. This study was approved by the UIH Institutional Review Board. Results Of 750 RTs performed, 47 recipients had prior or current HFrEF (age at transplant 54±13 years [mean±SD], 28% female, 45% with pre-RT LVEF <40%) (Table 1). Prior to RT, 23/47 (49%) of patients received RAASi. By 2 years, 15/47 (32%) had received a RAASi after a median 5.0 months. Among RAASi users, there was no significant increase in SCr or K, or decline in eGFR or MAP, during the follow-up period (Figure 1). A total of 24/47 (51%) had post-RT cardiology follow-up. Post-RT TTE was available in 19/47 (40%) patients at a median 7.6 months after RT and were more frequent in those with cardiology follow-up (63% vs 17%, p=0.003). Among 19 patients with post-RT TTE available, 6/19 (32%) had LVEF<50%, of whom none received post-RT RAASi. Conclusions In this single-center retrospective study of patients with HFrEF receiving RT, only 32% of RT recipients received RAASi, 51% had documented post-RT cardiology follow-up, and 43% had TTE. These findings suggest that RAASi are likely safe in patients with HFrEF following RT, and higher rates of cardiology follow-up with TTE may help identify patients that benefit from RAASi reintroduction.

cardiac & cardiovascular systems